A completely novel biologic for the treatment of rheumatoid arthritis is poised to enter the US market.
This is a preview of subscription content, log in via an institution to check access.
Author information
Authors and Affiliations
Related links
Rights and permissions
About this article
Cite this article
Garber, K. First-in-class biologic to enter rheumatoid arthritis fray. Nat Biotechnol 23, 1323–1324 (2005). https://doi.org/10.1038/nbt1105-1323
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1105-1323
- Springer Nature America, Inc.
This article is cited by
-
Cimzia's setback paves way for other TNF inhibitors in Crohn's disease
Nature Biotechnology (2007)
-
London's disastrous drug trial has serious side effects for research
Nature (2006)